Description
The combination of decitabine and cedazuridine is utilized to treat specific forms of myelodysplastic syndrome (conditions characterized by irregular blood cell production in the bone marrow, resulting in insufficient healthy blood cells), including chronic myelomonocytic leukemia (CMML) in adults. Decitabine belongs to the class of medications known as hypomethylation agents, which stimulate the bone marrow to produce normal blood cells and eliminate abnormal ones in the marrow. Cedazuridine, categorized as a cytidine deaminase inhibitor, enhances the concentration of decitabine in the body, amplifying the medication’s therapeutic effectiveness.